EP4327829A1 — Stabilization of lipid or lipidoid nanoparticle suspensions
Assigned to Ethris GmbH · Expires 2024-02-28 · 2y expired
What this patent protects
The invention relates to the use of a surfactant for stabilizing a suspension of lipid nanoparticles or of lipidoid nanoparticles in an aqueous vehicle solution against particle aggregation under a physical stress condition, wherein the lipid nanoparticles or lipidoid nanoparticl…
USPTO Abstract
The invention relates to the use of a surfactant for stabilizing a suspension of lipid nanoparticles or of lipidoid nanoparticles in an aqueous vehicle solution against particle aggregation under a physical stress condition, wherein the lipid nanoparticles or lipidoid nanoparticles comprise the following components (a) and (b): (a) a nucleic acid and (b) a permanently cationic lipid, an ionizable lipid or an ionizable lipidoid. In a related aspect, a method for stabilizing a suspension of lipid nanoparticles or of lipidoid nanoparticles in an aqueous vehicle solution against particle aggregation under a physical stress condition is provided.
Drugs covered by this patent
- Onpattro (PATISIRAN SODIUM) · Alnylam Pharmaceuticals
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.